July 27, 2015

REPRIEVE for Heart Disease in HIV

REPRIEVE was recently featured online in POZ. Click here to read more!
May 27, 2015

REPRIEVE and Washington University Featured in the St. Louis Post-Dispatch

Washington University's participation in the REPRIEVE trial is featured in the St. Louis Post-Dispatch!
May 1, 2015

Novel mechanisms and potential treatment strategies for CVD in HIV patients

Epidemiological studies suggest cardiovascular disease, including myocardial infarction and stroke, are increased 50% to 100% among HIV patients compared with non-HIV patients. Moreover, data suggest cardiovascular […]
April 24, 2015

Exciting News from MGH About the REPRIEVE Trial

Exciting news from Massachusetts General Hospital about the REPRIEVE trial!
April 15, 2015

NIH Announces REPRIEVE Trial Launch

NHLBI and NIAID announce launch of the REPRIEVE Trial:
March 13, 2015

Dr. Monica Shah Publishes on High Priority Research Including REPRIEVE Trial

Please see attached link to article “Stimulating High Impact HIV-Related Cardiovascular Research: Recommendations From a Multidisciplinary NHLBI Working Group on HIV-Related Heart, Lung, and Blood Disease” by Dr. Monica Shah published in the February 24, 2015 issue of the Journal of the American College of Cardiology.
March 11, 2015

Importance of REPRIEVE Trial Highlighted at CROI 2015

REPRIEVE Trial highlighted by Dr. Steven Grinspoon, Co-PI of the REPRIEVE Trial at HIV Conference/CROI 2015, in Seattle, WA.
March 10, 2015

Dr. Steven Grinspoon is Interviewed about REPRIEVE

At the 2015 Conference on Retroviruses and Opportunistic Infections (CROI Conference) in Seattle, Washington, Dr. Steven Grinspoon, Co-PI of the REPRIEVE trial, is interviewed on the topic of his plenary presentation: “Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action”.
October 27, 2014

MGH: Can statin treatment cut cardiovascular risk in HIV-infected patients?

BOSTON – A nationwide study based at Massachusetts General Hospital (MGH) will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus (HIV).